Synairgen has received approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of SNG001 (inhaled interferon-beta-1a) in coronavirus (COVID-19) patients. SNG001 will prevent cell damage in a similar fashion to that of multiple sclerosis (MS)